Aptevo Therapeutics Inc. (APVO)
| Bid | 1.95 |
| Market Cap | 11.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.7M |
| EPS (ttm) | 2680.54 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.01 |
| Analyst | Buy |
| Ask | 2 |
| Volume | 48,865 |
| Avg. Volume (20D) | 2,341,458 |
| Open | 2.04 |
| Previous Close | 2.04 |
| Day's Range | 1.93 - 2.05 |
| 52-Week Range | 1.72 - 381.10 |
| Beta | 5.63 |
About APVO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for APVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 days ago · accessnewswire.com
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business UpdateMipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types ...
1 month ago · marketwatch.com
Aptevo More Than Doubles After Favorable Results in Leukemia StudyAptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia s...
1 month ago · accessnewswire.com
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq RulesSEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...
1 month ago · accessnewswire.com
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed ...
